FDA Approved: MONTELUKAST — Supplemental Application (XLCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for montelukast from XLCare Pharmaceuticals Inc. under ANDA 202843.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Asthma
• Exercise-induced Bronchoconstriction

Drugs mentioned

• Montelukast (Montelukast)

Snippet

SUPPL AP for MONTELUKAST (MONTELUKAST)